Edition:
India

Mayne Pharma Group Ltd (MYX.AX)

MYX.AX on Australia Stock Exchange

0.38AUD
21 Feb 2020
Change (% chg)

$-0.03 (-6.25%)
Prev Close
$0.40
Open
$0.38
Day's High
$0.39
Day's Low
$0.36
Volume
9,777,371
Avg. Vol
4,415,886
52-wk High
$0.81
52-wk Low
$0.36

Latest Key Developments (Source: Significant Developments)

Mayne Pharma Group Posts FY Reported Net Loss Of $280.8 Mln
Friday, 23 Aug 2019 

Aug 23 (Reuters) - Mayne Pharma Group Ltd ::FY REVENUES OF $525.2 MILLION, DOWN 1%.FY REPORTED NET LOSS $280.8 MILLION VERSUS LOSS OF $133.9 MILLION.  Full Article

Mayne Pharma Operating Expenses Expected To Be Lower In Fy20 On Constant Currency Basis
Friday, 23 Aug 2019 

Aug 23 (Reuters) - Mayne Pharma Group Ltd ::OPERATING EXPENSES EXPECTED TO BE LOWER IN FY20 VERSUS FY19 ON A CONSTANT CURRENCY BASIS.  Full Article

FDA Approves Trade Name Lexette(Tm) (Halobetasol Propionate) Foam, 0.05%
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Mayne Pharma Group Ltd ::FDA APPROVES TRADE NAME LEXETTE(TM) (HALOBETASOL PROPIONATE) FOAM, 0.05%.  Full Article

Mayne Pharma Group Announces Launch Of Tolsura (Suba-Itraconazole) In United States
Wednesday, 30 Jan 2019 

Jan 30 (Reuters) - Mayne Pharma Group Ltd ::ANNOUNCES LAUNCH OF TOLSURA (SUBA-ITRACONAZOLE) IN UNITED STATES.  Full Article

Mayne Pharma Group Announces Us Commercial Rights For Suba-Itraconazole In Basal Cell Carcinoma Nevus Syndrome
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Mayne Pharma Group Ltd ::MAYNE PHARMA GROUP LTD - ANNOUNCES US COMMERCIAL RIGHTS FOR SUBA-ITRACONAZOLE IN BASAL CELL CARCINOMA NEVUS SYNDROME.  Full Article

Mayne Pharma Receives FDA Approval Of Tolsura For Treatment Of Certain Fungal Infections
Wednesday, 12 Dec 2018 

Dec 11 (Reuters) - Mayne Pharma Group Ltd ::MAYNE PHARMA RECEIVES FDA APPROVAL OF TOLSURA™ (SUBA®-ITRACONAZOLE CAPSULES) FOR THE TREATMENT OF CERTAIN FUNGAL INFECTIONS.MAYNE PHARMA GROUP LTD - WILL DIRECTLY COMMERCIALISE TOLSURA AND PLANS TO LAUNCH IN JANUARY 2019.  Full Article

Mayne Pharma Group Says FDA Approved New Drug Application For Tolsura™ (Suba®-Itraconazole) 65Mg Capsules
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Mayne Pharma Group Ltd ::FDA HAS APPROVED NEW DRUG APPLICATION (NDA) FOR TOLSURA™ (SUBA®-ITRACONAZOLE) 65MG CAPSULES.  Full Article

Mayne Pharma Group Acquires Halobetasol Foam 0.05 pct
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Mayne Pharma Group Ltd ::ACQUIRED HALOBETASOL FOAM 0.05% FOR AN INVESTMENT OF UP TO US$32.0 MILLION AND AN ONGOING EARN OUT PAYMENT.MAYNE PHARMA WILL FUND ACQUISITION FROM CASH AND UNDRAWN DEBT.MAYNE PHARMA WILL FUND ACQUISITION FROM CASH AND UNDRAWN DEBT.EXPECTED TO BE ACCRETIVE TO EARNINGS IN FIRST FULL YEAR FOLLOWING COMMERCIALISATION (FY20).ANTICIPATES SPENDING APPROXIMATELY US$4 MILLION IN FY19 TO LAUNCH HALOBETASOL FOAM.EXPECTS PEAK SALES POTENTIAL TO EXCEED US$25 MILLION.  Full Article

Mayne Pharma Group Posts FY Loss Attributable $92.4 MILLION
Friday, 24 Aug 2018 

Aug 24 (Reuters) - Mayne Pharma Group Ltd ::FY REVENUE FROM ORDINARY ACTIVITIES $530.3 MILLION VERSUS $572.6 MILLION.FY LOSS ATTRIBUTABLE $92.4 MILLION VERSUS PROFIT $71.1 MILLION.NO FINAL DIVIDEND IN RESPECT OF FINANCIAL YEAR ENDED 30 JUNE.  Full Article

Mayne Pharma Says Acquired Generic Efudex From Spear Pharmaceuticals
Monday, 23 Jul 2018 

July 23 (Reuters) - Mayne Pharma Group Ltd ::MAYNE PHARMA ACQUIRES GENERIC EFUDEX IN THE US.ACQUIRED GENERIC EFUDEX (FLUOROURACIL CREAM 5%) FROM SPEAR PHARMACEUTICALS FOR UP TO US$30 MLN.WILL FUND ACQUISITION FROM CASH AND UNDRAWN DEBT.  Full Article